Clinical impact of molecular biomarkers in gliomas

被引：62

作者：

Siegal, Tali ^{[1
]}

机构：

[1] Rabin Med Ctr, Davidoff Inst Oncol, Ctr Neurooncol, IL-49100 Petah Tiqwa, Israel

来源：

JOURNAL OF CLINICAL NEUROSCIENCE | 2015年 / 22卷 / 03期

关键词：

Astrocytoma; Biomarkers; Glioma; Oligodendroglioma; Predictive; Prognostic; MGMT PROMOTER METHYLATION; NEWLY-DIAGNOSED GLIOBLASTOMA; INTEGRATED GENOMIC ANALYSIS; OLIGODENDROGLIAL TUMORS; IDH1; MUTATIONS; MALIGNANT ASTROCYTOMAS; DNA METHYLATION; FREQUENT ATRX; MUTANT IDH1; TEMOZOLOMIDE;

D O I：

10.1016/j.jocn.2014.10.004

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The World Health Organization (WHO) classification system for glial tumors provides guidance as to the predicted course of the disease and choice of treatment. However, histologically identical tumors may have a very different outcome and response to treatment. Molecular markers that carry both diagnostic and prognostic information add valuable tools by redefining tumor subtypes within each WHO category. Therefore, molecular biomarkers have become an integral part of tumor assessment in modern neuro-oncology and biomarker status now guides clinical decisions in some subtypes of gliomas, including anaplastic oligodendroglioma and glioblastoma in the elderly. This review discusses the prognostic and predictive impact of molecular markers that have undergone extensive study in recent years. The clinical relevance of contemporary molecular classification of gliomas using the routine assessment of IDH mutations, promoter methylation of MGMT, chromosomal deletion of 1p/19q, mutations of EGFR and ATRX genes, and BRAE fusion or point mutation is highlighted. The potential of molecular biomarker-based classification to guide future therapeutic approach is discussed and accentuated. (C) 2014 Elsevier Ltd. All rights reserved.

引用

页码：437 / 444

页数：8

共 82 条

[1] The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas [J].

Abedalthagafi, Malak ;

Phillips, Joanna J. ;

Kim, Grace E. ;

Mueller, Sabine ;

Haas-Kogen, Daphne A. ;

Marshall, Roxanne E. ;

Croul, Sidney E. ;

Santi, Mariarita R. ;

Cheng, Jing ;

Zhou, Shengmei ;

Sullivan, Lisa M. ;

Martinez-Lage, Maria ;

Judkins, Alexander R. ;

Perry, Arie .

MODERN PATHOLOGY, 2013, 26 (11) :1425-1432

[2] Intercellular transfer of the oncogenic receptor EGFrvIII by microvesicles derived from tumour cells [J].

Al-Nedawi, Khalid ;

Meehan, Brian ;

Micallef, Johann ;

Lhotak, Vladimir ;

May, Linda ;

Guha, Abhijit ;

Rak, Janusz .

NATURE CELL BIOLOGY, 2008, 10 (05) :619-U24

[3] IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours [J].

Amary, M. Fernanda ;

Bacsi, Krisztian ;

Maggiani, Francesca ;

Damato, Stephen ;

Halai, Dina ;

Berisha, Fitim ;

Pollock, Robin ;

O'Donnell, Paul ;

Grigoriadis, Anita ;

Diss, Tim ;

Eskandarpour, Malihe ;

Presneau, Nadege ;

Hogendoorn, Pancras C. W. ;

Futreal, Andrew ;

Tirabosco, Roberto ;

Flanagan, Adrienne M. .

JOURNAL OF PATHOLOGY, 2011, 224 (03) :334-343

[4] Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate [J].

Andronesi, Ovidiu C. ;

Rapalino, Otto ;

Gerstner, Elizabeth ;

Chi, Andrew ;

Batchelor, Tracy T. ;

Cahil, Dan P. ;

Sorensen, A. Gregory ;

Rosen, Bruce R. .

JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (09) :3659-3663

[5]

[Anonymous], 2013, CLIN PRACT GUID ONC

[6] Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma [J].

Babu, Ranjith ;

Adamson, D. Cory .

CORE EVIDENCE, 2012, 7 :93-103

[7] IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection [J].

Beiko, Jason ;

Suki, Dima ;

Hess, Kenneth R. ;

Fox, Benjamin D. ;

Cheung, Vincent ;

Cabral, Matthew ;

Shonka, Nicole ;

Gilbert, Mark R. ;

Sawaya, Raymond ;

Prabhu, Sujit S. ;

Weinberg, Jeffrey ;

Lang, Frederick F. ;

Aldape, Kenneth D. ;

Sulman, Erik P. ;

Rao, Ganesh ;

McCutcheon, Ian E. ;

Cahill, Daniel P. .

NEURO-ONCOLOGY, 2014, 16 (01) :81-91

[8] Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3 T: A phantom study [J].

Bertolino, Nicola ;

Marchionni, Chiara ;

Ghielmetti, Francesco ;

Burns, Brian ;

Finocchiaro, Gaetano ;

Anghileri, Elena ;

Bruzzone, Maria Grazia ;

Minati, Ludovico .

PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2014, 30 (06) :702-707

[9] MUTAGENESIS AND LAUE STRUCTURES OF ENZYME INTERMEDIATES - ISOCITRATE DEHYDROGENASE [J].

BOLDUC, JM ;

DYER, DH ;

SCOTT, WG ;

SINGER, P ;

SWEET, RM ;

KOSHLAND, DE ;

STODDARD, BL .

SCIENCE, 1995, 268 (5215) :1312-1318

[10] Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping [J].

Borger, Darrell R. ;

Tanabe, Kenneth K. ;

Fan, Kenneth C. ;

Lopez, Hector U. ;

Fantin, Valeria R. ;

Straley, Kimberly S. ;

Schenkein, David P. ;

Hezel, Aram F. ;

Ancukiewicz, Marek ;

Liebman, Hannah M. ;

Kwak, Eunice L. ;

Clark, Jeffrey W. ;

Ryan, David P. ;

Deshpande, Vikram ;

Dias-Santagata, Dora ;

Ellisen, Leif W. ;

Zhu, Andrew X. ;

Iafrate, A. John .

ONCOLOGIST, 2012, 17 (01) :72-79

← 1 2 3 4 5 6 7 8 9 →